Revolution Medicines’ pan-RAS inhibitor daraxonrasib delivered a major survival gain in phase 3 RASolute 302 for advanced pancreatic ductal adenocarcinoma, nearly doubling median survival versus chemotherapy. The trial results—reported at ASCO 2026 and published in the New England Journal of Medicine—showed patients on daraxonrasib lived 13.2 months versus 6.7 months with standard-of-care. The study also reported longer time to progression, with disease worsening not seen until a median of 7.2 months on daraxonrasib versus 3.6 months on chemotherapy. With more than 90% of enrolled patients harboring the most common RAS mutation, the design strengthens confidence in broad applicability within RAS-driven PDAC. The readout further signals that multi-member RAS pathway inhibition may overcome limitations seen with earlier, narrower KRAS-targeting approaches. As pancreatic cancer remains one of the highest-mortality solid tumors, the data adds momentum to a crowded “undruggable” target space and is likely to shape near-term trial strategy and competitive positioning. Clinically, the results point toward an evidence base for RAS pathway blockade as a new backbone option in later-line PDAC—while highlighting the need for continued study of resistance patterns and patient selection.